MSD began worldwide recruitment for the trial and subjects are currently being enrolled. In the randomised trial, the ...

The US company’s rabies candidate, RBI-4000, was able to elicit an immune response comparable to Bavarian Nordic’s RavAvert.

A new HPV vaccine induced regression of precancerous cervical lesions in 50% of patients and led to viral clearance in some ...

Gene therapies to treat rheumatoid arthritis have evolved slowly, but one is ready to move into human trials and an ...

ACLF clinical trials expected to initiate in 1Q253 clinical data readouts expected by year-end 2025 across the ACLF pipeline, including on-going UNVEIL-IT® Phase 2 trialData of on-going Phase 1b ...

Breakthrough research and investor enthusiasm prompted Cullinan Therapeutics to redirect one of its cancer programs toward ...

Q4 2024 Earnings Call Transcript February 6, 2025 Neurocrine Biosciences, Inc. misses on earnings expectations. Reported EPS ...

IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Get Free Report) has earned an average rating of “Moderate Buy” from the sixteen analysts that are covering the firm, Marketbeat.com reports. Two research ...

The art of saying no in clinical trials goes beyond simply delivering news; it involves maintaining relationships and ...

IRVINE, Calif. - Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN), a biotechnology company with a market capitalization of $284.54 million and a remarkable 170% stock return over the past year according to ...

Financial writer discusses Coya Therapeutics, Inc.'s Treg therapies for neurodegenerative diseases like ALS, FTD, and PD.

MAIA Biotechnology, Inc. (NYSEAMERICAN: MAIA) disclosed information relating to its Phase 2 THIO-101 trial in advanced non-small cell lung cancer through a press release on February 4, 2025. According ...